Prothena Receives Buy Rating from Citizens JMP Analyst Jason Butler, Price Target Set at $29.00

Citizens JMP analyst Jason Butler reiterated a Buy rating on Prothena with a price target of $29.00, following the company's Q1 revenue of $2.83 million and GAAP net loss of $60.2 million. Butler has a 43.40% success rate and an average return of 6.7%. However, corporate insider sentiment is negative due to an increase in insider selling.

Prothena (PRTA) reported a quarterly loss of $1.86 per share for the quarter ended June 2025, falling short of the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.22 per share a year ago. The company's quarterly report represents an earnings surprise of -67.57%, as it missed the expected loss of $0.92 per share by a significant margin [1].

Revenue for the quarter was $4.42 million, a substantial decline from the year-ago figure of $132.01 million and a 79.2% miss of the Zacks Consensus Estimate. This marks the company's fourth consecutive quarter of missing revenue estimates. Prothena's stock has lost approximately 50.8% since the beginning of the year, contrasting with the S&P 500's gain of 6.1% [1].

Citizens JMP analyst Jason Butler reiterated a Buy rating on Prothena with a price target of $29.00 following the company's Q1 revenue of $2.83 million and GAAP net loss of $60.2 million. Butler's track record includes a 43.40% success rate and an average return of 6.7%. However, corporate insider sentiment remains negative due to increased insider selling [1].

Prothena's immediate price movement will largely depend on management's commentary during the earnings call. The company's earnings outlook, including current consensus expectations for the coming quarter and the current fiscal year, will be crucial for investors. The consensus EPS estimate for the coming quarter is -$0.96 on $24.8 million in revenues, while the estimate for the current fiscal year is -$3.94 on $39.34 million in revenues [1].

In the broader context, the Medical - Biomedical and Genetics industry, to which Prothena belongs, is currently ranked in the bottom 43% of the 250 plus Zacks industries. The top 50% of Zacks-ranked industries tend to outperform the bottom 50% by a factor of more than 2 to 1 [1].

Another notable company in the industry, Gyre Therapeutics, Inc. (GYRE), is expected to report quarterly earnings of $0.03 per share for the quarter ended June 2025, representing a year-over-year change of +200%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days [1].

References:
[1] https://finance.yahoo.com/news/prothena-prta-reports-q2-loss-215003682.html